Categories: CancerHealthcareNews

NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan(R) in Ovarian and Related Cancers

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

LEXINGTON, KY / ACCESSWIRE / March 5, 2024 / NX Development Corp. (NXDC) has achieved another milestone as we proudly announce the recent granting of orphan-drug status by the U.S. Food and Drug Administration (FDA) for Gleolan (aminolevulinic acid HCl). This designation was provided for the “real-time detection and visualization of epithelial ovarian tumors during debulking surgery.”

NXDC Logo
Logo of NXDC

Dr. Salvatore DeSena, CEO of NX Development Corp., shared this excitement, stating, “On behalf of our entire team, I am proud to announce that NX Development Corp. secured orphan-drug status for Gleolan in ovarian, fallopian tube, and primary peritoneal cancer. This achievement demonstrates NXDC’s commitment to exploring new and innovative uses for Gleolan to help patients and surgeons in their fight against these cancers.”

“This important milestone underlines the capabilities of aminolevulinic acid HCl in fluorescence-guided surgery. As a group, we aim to expand this further, also to other countries as well, providing support to patients and healthcare professionals combating cancer globally,” said Dr. Ulrich Kosciessa, Chairman of the Board of NXDC and CEO of photonamic GmbH & Co KG. (Pinneberg, Germany), parent company to NXDC.

Gleolan is an optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. Gleolan has gained clinical recognition for its use in visualizing malignant glioma tissue during surgery.

About NX Development Corp.: NX Development Corp., a wholly-owned subsidiary of photonamic GmbH & Co. KG., a member of the SBI Holdings Inc. Group (Tokyo, Japan), is dedicated to revolutionizing cancer care through innovative solutions and groundbreaking developments in fluorescence-guided surgery.

About Gleolan

Contact Information

Raquel R.
adminpeopledept@nxdevcorp.com

Alicia M.
mediamarketing@nxdevcorp.com

SOURCE: NX Development Corp.

View the original press release on newswire.com.

Staff

Recent Posts

As Sober.Buzz Community Explodes Its Growth Globally it is Announcing “Spreading the Good BUZZ” Podcast Hosted by Josh Case Debuting July 7th

Sober.Buzz's Online Store that includes the Exclusive Inspirational Collection by Heidi Case has Launched. Additionally,…

10 hours ago

STUDENTS STEP INTO THE ROLE OF ATHLETIC TRAINERS, CARDIOLOGISTS, DIETITIANS, AND MORE WITH FREE SUMMER SCIENCE PROGRAM!

GSK Science in the Summer™ Unveils New 2025 Theme: Be A Health Scientist! PHILADELPHIA, June…

10 hours ago

Healthy Interactions Expands Primary Care Alliance to Improve Cardiometabolic Care

JACKSON HOLE, Wyo., June 18, 2025 /PRNewswire/ -- Healthy Interactions LLC, a global leader in…

10 hours ago

RevelAi Health Secures $3.1 Million Seed Funding to Scale Artificial Intelligence Care Coordination for Musculoskeletal Health

DURHAM, N.C., June 18, 2025 /PRNewswire/ -- RevelAi Health, a conversational artificial intelligence (AI) platform…

10 hours ago

Atlanta Hair Transplant and Restoration Specialist Dr. Benjamin Stong Now Accepting Bitcoin (BTC) for Hair Transplant Procedures at KalosHairTransplant.com

Dr. Benjamin Stong, founder of Kalos Hair Transplant in Atlanta, is now accepting Bitcoin (BTC)…

10 hours ago